Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2020

Nov 16, 2020

SELL
$26.5 - $55.4 $530,000 - $1.11 Million
-20,000 Closed
0 $0
Q2 2020

Aug 14, 2020

BUY
$26.15 - $35.45 $523,000 - $709,000
20,000 New
20,000 $632,000

Others Institutions Holding PCVX

About Vaxcyte, Inc.


  • Ticker PCVX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,315,100
  • Market Cap $4.43B
  • Description
  • Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...
More about PCVX
Track This Portfolio

Track Pinz Capital Management, LP Portfolio

Follow Pinz Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pinz Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Pinz Capital Management, LP with notifications on news.